---
title: "Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285577132.md"
description: "Bank of America Securities has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $62.00. Analyst Jason Gerberry, a 5-star analyst with an 18.9% average return, highlights Royalty Pharma's Strong Buy consensus and a price target consensus of $59.43. Gerberry also covers other healthcare stocks like BioMarin Pharmaceutical and Ionis Pharmaceuticals."
datetime: "2026-05-07T13:59:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285577132.md)
  - [en](https://longbridge.com/en/news/285577132.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285577132.md)
---

# Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Royalty Pharma, with a price target of $62.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Gerberry is a 5-star analyst with an average return of 18.9% and a 61.32% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ionis Pharmaceuticals, and Alkermes.

Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $59.43.

### Related Stocks

- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)